Lymphocyte immune globulin, anti-thymocyte globulin (equine) - Biologic Drug Details

Summary for lymphocyte immune globulin, anti-thymocyte globulin (equine)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for lymphocyte immune globulin, anti-thymocyte globulin (equine)

Mechanism of Action	Antibody-Surface Protein Interactions
Physiological Effect	Increased T Lymphocyte Destruction Lymphocyte Function Alteration
Established Pharmacologic Class	Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for lymphocyte immune globulin, anti-thymocyte globulin (equine) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for lymphocyte immune globulin, anti-thymocyte globulin (equine) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for lymphocyte immune globulin, anti-thymocyte globulin (equine) Derived from Patent Text Search

No patents found based on company disclosures

Lymphocyte immune globulin, anti-thymocyte globulin (equine) Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine)

Introduction

Lymphocyte immune globulin, specifically anti-thymocyte globulin (ATG) derived from equine sources, is a biologic drug used in various medical treatments, including the prevention of renal transplant rejection and the treatment of aplastic anemia. This article delves into the market dynamics and financial trajectory of this crucial biologic drug.

Market Size and Growth

The global immunoglobulin market, which includes anti-thymocyte globulin, is experiencing significant growth. In 2022, the market was valued at approximately $13.5 billion and is projected to reach $25.6 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032[1][4].

Key Drivers of Market Growth

Several factors are driving the growth of the immunoglobulin market, including:

Prevalence of Target Diseases

Diseases such as primary immunodeficiency, myasthenia gravis, and idiopathic thrombocytopenic purpura are on the rise, creating a substantial demand for immunoglobulin therapies. For instance, around 8 million people globally are affected by primary immunodeficiency, and myasthenia gravis affects approximately 36,000 to 60,000 individuals in the U.S.[1].

Growing Geriatric Population

The increasing geriatric population, which is more susceptible to immune-related disorders, further fuels the demand for immunoglobulin treatments.

Healthcare Infrastructure and Adoption

Regions like North America, with well-developed healthcare infrastructures, are leading the market due to their proactive adoption of advanced medical treatments. This infrastructure enables efficient delivery of immunoglobulin therapies, contributing to the region's dominant market position[1][4].

Regional Market Analysis

North America

North America accounted for the largest share of the immunoglobulin market in 2022 and is expected to remain dominant during the forecast period. The region's robust healthcare framework, high prevalence of diseases requiring immunoglobulin therapies, and proactive adoption of advanced treatments are key factors driving this growth[1][4].

Asia-Pacific

The Asia-Pacific region is anticipated to witness significant growth due to a large population base, increased healthcare awareness, and a surge in cases of immunodeficiency disorders and autoimmune diseases. Government initiatives, pharmaceutical market expansion, and increased research and development activities are also contributing to the region's accelerated growth[1].

Specific Use Cases for Anti-Thymocyte Globulin (Equine)

Renal Transplant Rejection

Equine anti-thymocyte globulin (ATG) is used to suppress the immune system and prevent renal transplant rejection. It targets various immune system proteins, including lymphocyte surface proteins, granulocytes, platelets, and bone marrow cells, inducing T cell apoptosis and resulting T-cell lymphopenia[3].

Aplastic Anemia

ATG is also indicated for the treatment of aplastic anemia, where it helps in restoring the bone marrow's ability to produce blood cells.

Cost Effectiveness and Clinical Benefits

Quality-Adjusted Life Expectancy

Studies have shown that while intravenous immune globulin therapy can reduce the rate of bacterial infections, it may result in a loss of quality-adjusted life expectancy when the inconvenience of treatment is taken into account. However, if the inconvenience is not considered, the therapy can result in a gain of 0.8 quality-adjusted days per patient per year at a significant cost[2].

Financial Implications

The cost of intravenous immune globulin therapy is substantial, estimated at $6 million per quality-adjusted life-year gained. This high cost underscores the need for careful decision-analysis modeling to assess the clinical and financial effects of adopting such interventions in medical practice[2].

Regulatory and Research Landscape

FDA and Research Initiatives

The FDA and other regulatory bodies are involved in promoting and funding basic and applied research relevant to immune globulin products. This includes studies on the efficacy of these products, the discovery and development of novel treatments, and the amplification of durable responses to vaccines. The focus on understanding plasma cells and their role in antibody production is a significant area of research[5].

Market Expansion and Product Approvals

Increasing Product Approvals

The rising number of approvals for the use of immunoglobulins in treating immunodeficiency disorders is a major driver of market expansion. Clinicians are increasingly inclined towards immunodeficiency therapies, further propelling market growth[4].

Consumer Awareness and Healthcare Costs

Rising healthcare costs and increased consumer awareness of products used to treat immunodeficiency disorders are also contributing to the market's growth. Studies highlighting the prevalence of hypogammaglobulinemia in patients with chronic lymphocytic leukemia have further emphasized the need for these therapies[4].

Key Takeaways

• The global immunoglobulin market, including anti-thymocyte globulin, is projected to grow significantly, driven by the prevalence of target diseases and a growing geriatric population.
• North America is the largest market, but the Asia-Pacific region is expected to witness notable growth.
• Anti-thymocyte globulin is crucial in preventing renal transplant rejection and treating aplastic anemia.
• The cost-effectiveness of intravenous immune globulin therapy is a critical consideration, with significant financial implications.
• Regulatory bodies and research initiatives are key in advancing the understanding and application of immune globulin products.

FAQs

What is the projected growth rate of the global immunoglobulin market?

The global immunoglobulin market is projected to grow at a CAGR of 6.6% from 2023 to 2032[1].

What are the primary use cases for anti-thymocyte globulin (equine)?

Anti-thymocyte globulin (equine) is primarily used to prevent renal transplant rejection and to treat aplastic anemia[3].

How does the cost-effectiveness of intravenous immune globulin therapy impact its use?

Intravenous immune globulin therapy can be costly, with an estimated $6 million per quality-adjusted life-year gained, which may affect its adoption despite its clinical benefits[2].

Which region is expected to witness significant growth in the immunoglobulin market?

The Asia-Pacific region is anticipated to witness significant growth due to a large population base, increased healthcare awareness, and a surge in cases of immunodeficiency disorders and autoimmune diseases[1].

What role do regulatory bodies play in the development of immune globulin products?

Regulatory bodies like the FDA promote and fund research relevant to immune globulin products, focusing on efficacy, novel treatments, and durable responses to vaccines[5].

Sources

1. Allied Market Research - Immunoglobulin Market Size, Growth Analysis| Forecast- 2032
2. PubMed - Cost effectiveness of prophylactic intravenous immune globulin in patients with chronic lymphocytic leukemia and hypogammaglobulinemia
3. DrugBank - Antilymphocyte immunoglobulin (horse)
4. Straits Research - Immunoglobulin Market Size, Growth and Forecast to 2031
5. FDA - Immune Globulin Potency In The 21st Century